Analyst firms · Morgan Stanley · HON

Morgan Stanley HON price target and rating history

Honeywell International Inc. (HON) · Industrials

Morgan Stanley rates Honeywell International Inc. (HON) Equal-Weight with a $210 price target, as of its latest action on Sep 6, 2024. It has published 4 rating actions on HON since October 2021, including 0 upgrades and 0 downgrades. Across 11 firms with a HON price target in the last 12 months, the median target is $255.

Current rating
Equal-Weight
Price target
$210
Median target, all firms
$255
Actions on HON
4

Morgan Stanley price target on HON

$229$220$21020222023202420252026
Morgan Stanley price target on HON, each point a stated target, October 2021 to September 2024.

Every Morgan Stanley rating on HON

How other firms rate HON

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoEqual Weight$231Sep 25, 2026
MeliusHold$190Sep 14, 2026
JefferiesHold$255Aug 17, 2026
BofA SecuritiesNeutral$265Jul 28, 2026
DaiwaOutperform$255Jun 30, 2026
BernsteinMkt Perform$233Jun 10, 2026
BMO Capital MarketsOutperform$273Mar 27, 2026
Wolfe ResearchOutperform$293Feb 27, 2026
Vertical ResearchHold$220Jan 5, 2026
Evercore ISIOutperform$255Dec 15, 2025
BNP Paribas ExaneNeutral$195Dec 3, 2025

Questions about Morgan Stanley and HON

What is Morgan Stanley's price target for HON?
Morgan Stanley's latest stated price target for Honeywell International Inc. (HON) is $210, from its action on Sep 6, 2024.
What is Morgan Stanley's rating on HON?
Morgan Stanley rates HON Equal-Weight, a neutral rating, as of Sep 6, 2024.
When did Morgan Stanley last change its view on HON?
On Sep 6, 2024, Morgan Stanley starts coverage at Equal-Weight, price target $210.
How does Morgan Stanley's HON target compare with other analysts?
Across 11 firms with a HON price target in the last 12 months, the median target is $255.

More HON rating histories

All Morgan Stanley ratingsHON news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.